Fenfluramine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Fenfluramine

Examples of brand names: Fintepla [EU/DE]

ATC code: N03AX26

Main use (for orientation): Severe epilepsy syndromes

Documented research summary

Prescribing information: fenfluramine AUC +59%, Cmax +10%; norfenfluramine AUC −22%, Cmax −33%. The regulatory assessment expects no clinically significant interaction; this is not a general safety guarantee.

Uncertainties and limitations

CBD dose not specified in the fenfluramine label paragraph read; no dose invented. Do not equate clinical endpoints with pharmacokinetics.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Direct pair finding

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Pair-specific evidence, distinguished in the individual findings

Mechanism / drug context: With CBD, fenfluramine exposure increases and norfenfluramine exposure decreases; measured human pharmacokinetics.

Type of supporting material: See the separate original findings

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Fenfluramine is active, with active metabolite norfenfluramine. Not solely a prodrug.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [CA_L_D0057]: Pair finding

Statement supported: Fenfluramine AUC +59%, Cmax +10%; norfenfluramine AUC −22%, Cmax −33%.

Source: FINTEPLA (FENFLURAMINE) SOLUTION [UCB, INC.] [CA_L_D0057]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – clinically studied

Finding ID: V6_D0057_1

Type of result: Finding within the documented study context

Observation: Fenfluramine AUC +59%, Cmax +10%; norfenfluramine AUC −22%, Cmax −33%.

Mechanism: Change in parent substance/active metabolite

Study type: Interaction study according to prescribing information

Context studied: Single dose of fenfluramine after repeated CBD.

Clinical interpretation: No clinically significant interaction expected in the regulatory assessment.

Limitations and uncertainties: No harm endpoint; do not generalise to all preparations/people.

Original sources for this finding: FINTEPLA (FENFLURAMINE) SOLUTION [UCB, INC.] [CA_L_D0057]

References and access status

[CA_L_D0057] FINTEPLA (FENFLURAMINE) SOLUTION [UCB, INC.]

Original source / bibliographic reference

Authors: UCB, Inc.

Year: 2025

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility